ACP-105
Muscle Growth & Body CompositionAlso known as: ACP105, Acadia SARM
Mechanism
ACP-105 is a partial androgen receptor agonist developed by Acadia Pharmaceuticals. As a partial agonist, it provides anabolic stimulation in muscle and bone with potentially fewer side effects than full AR agonists. Preclinical data suggests it may be well-suited for osteoporosis and muscle wasting with a favorable safety profile.
Technical detail
ACP-105 is a non-steroidal partial AR agonist developed by Acadia Pharmaceuticals. It demonstrates approximately 66% of the anabolic efficacy of testosterone in the levator ani muscle assay while exhibiting only ~21% of the androgenic activity on the prostate, yielding a favorable therapeutic index. As a partial agonist, it may compete with endogenous androgens in high-androgen tissues (prostate) while providing net agonism in low-androgen-threshold tissues (muscle, bone). Preclinical data showed reversal of orchidectomy-induced bone and muscle loss.